https://en.bioecon.ru/companies/gilead-sciences/Recent content in Gilead-Sciences on BioeconHugoen-USSat, 08 Aug 2026 23:37:59 +0700https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Sat, 08 Aug 2026 00:00:00 +0000https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/A monoclonal antibody chemically linked to a highly potent cytotoxic payload, delivering chemotherapy-grade cell killing selectively to antigen-expressing tumor cells — one of oncology’s clearest recent commercial successes, and also a field where a Phase 3 win on efficacy can still surface a real mortality signal.https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.